Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.02 | — | 0.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 7.50 | 3.22 | 0.03 | 18.83 | 133.96 | 269.73 | 24873.71 | 438.23 | 478.53 | 395.44 | 578.15 | 334.41 | 800.15 | 1251.21 | 12003.24 | 511.85 | 453.63 | 1735.50 | 313.30 | — | — |
| — | -98.8% | -100.0% | -95.7% | -72.0% | -31.8% | +4202.3% | +31.0% | -40.2% | -68.4% | -95.2% | -34.7% | +76.4% | -27.9% | +3731.2% | — | — | — | — | — | — | |
| P/B Ratio | 0.15 | 0.23 | 0.13 | 0.74 | — | — | — | — | — | — | 298.11 | 131.56 | 114.40 | 109.04 | 61.65 | 73.38 | 77.14 | 68.27 | 79.09 | 53.61 | 69.86 |
| — | — | — | — | — | — | — | — | — | — | +383.6% | +79.3% | +48.3% | +59.7% | -22.1% | +36.9% | +10.4% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 0.45 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 0.41 | 1.82 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 20.0% | -69.3% | 99.8% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | 20.0% | 29.2% | 54.6% | -377.4% | 20.5% | 19.3% | 29.9% | 20.0% | 20.0% | 36.7% | 57.4% | — | — |
| — | -446.3% | +399.2% | -0.0% | -0.0% | -31.4% | -63.3% | +105.3% | -2.4% | +50.8% | +82.3% | -1987.2% | +2.4% | -47.4% | -47.9% | — | — | — | — | — | — | |
| Operating Margin | -20757.6% | -2335.6% | 49.5% | -10912.3% | -20995.9% | -52886.7% | -38811.5% | -800.3% | -865.4% | -2445.8% | -665.1% | -813.3% | -595.2% | -724.2% | -12798.9% | -422.4% | -222.2% | -773.4% | -60.3% | — | — |
| — | +95.6% | +100.1% | -1263.5% | -2326.2% | -2062.3% | -5735.5% | +1.6% | -45.4% | -237.7% | +94.8% | -92.5% | -167.9% | +6.4% | -21114.9% | — | — | — | — | — | — | |
| Net Margin | -14677.1% | -3849.9% | 63.2% | 2662.8% | -29183.2% | -29431.0% | -43373.6% | -854.4% | -915.1% | -2469.1% | -662.8% | -806.7% | -578.9% | -691.1% | -12106.8% | -403.9% | -216.4% | -773.1% | -66.0% | — | — |
| — | +86.9% | +100.1% | +411.7% | -3089.0% | -1092.0% | -6443.8% | -5.9% | -58.1% | -257.3% | +94.5% | -99.7% | -167.6% | +10.6% | -18247.0% | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -287.9% | -79.1% | 96.9% | 218.8% | — | — | — | — | — | -1252.0% | -67.3% | -57.2% | -18.8% | -14.1% | -14.5% | -13.5% | -8.8% | -7.3% | -4.1% | -6.0% | -13.0% |
| — | — | — | — | — | — | — | — | — | -8801.4% | -364.7% | -322.3% | -113.4% | -91.5% | -254.0% | -124.6% | +32.3% | +72.7% | +81.3% | -142.1% | — | |
| ROA | -29.1% | -19.3% | 15.9% | 2.9% | -16.8% | -7.0% | -7.8% | -11.9% | -14.6% | -53.4% | -25.3% | -33.3% | -13.2% | -10.4% | -11.2% | -11.0% | -7.9% | -7.1% | -3.9% | -5.8% | -11.8% |
| — | -176.2% | +305.0% | +124.2% | -14.6% | +86.9% | +69.3% | +64.3% | -11.2% | -414.8% | -125.7% | -201.7% | -65.9% | -45.3% | -185.0% | -91.2% | +32.8% | +66.3% | +80.4% | -143.1% | — | |
| ROIC | -171.1% | -19.5% | 25.9% | -37.1% | -57.2% | -60.6% | -45.2% | -116.1% | -125.8% | -145.4% | -38.5% | -45.7% | -16.3% | -14.0% | -19.1% | -19.2% | -11.2% | -8.4% | -4.0% | -6.0% | -14.4% |
| — | +67.9% | +157.3% | +68.0% | +54.5% | +58.3% | -17.6% | -154.0% | -674.3% | -938.3% | -101.5% | -138.1% | -45.0% | -66.4% | -380.7% | -222.1% | +22.0% | +82.2% | +91.1% | -140.3% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.46 | 0.88 | 1.14 | 2.46 | — | — | — | — | — | — | 0.96 | 0.47 | 0.27 | 0.23 | 0.20 | 0.17 | 0.15 | 0.01 | 0.01 | — | — |
| — | — | — | — | — | — | — | — | — | — | +390.7% | +173.5% | +80.3% | +3841.6% | +3055.2% | — | — | — | -63.1% | — | — | |
| Debt / EBITDA | — | — | 1.95 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.11 | 0.06 | 0.09 | 0.11 | 0.06 | 0.11 | 0.07 | 0.19 | 0.07 | 0.10 | 0.46 | 0.73 | 2.56 | 4.36 | 6.62 | 11.52 | 12.52 | 30.26 | 26.74 | 17.44 | 18.19 |
| — | -43.4% | +23.5% | -43.6% | -15.1% | +5.0% | -84.9% | -73.7% | -97.3% | -97.6% | -93.0% | -93.6% | -79.6% | -85.6% | -75.2% | -33.9% | -31.2% | +1739.6% | +267.6% | +43.7% | — | |
| Quick Ratio | 0.11 | 0.06 | 0.09 | 0.11 | 0.06 | 0.11 | 0.07 | 0.19 | 0.07 | 0.10 | 0.46 | 0.73 | 2.56 | 4.36 | 6.62 | 11.05 | 12.52 | 30.26 | 26.74 | 17.44 | 17.36 |
| — | -43.4% | +23.5% | -43.6% | -15.1% | +5.0% | -84.9% | -73.7% | -97.3% | -97.6% | -93.0% | -93.4% | -79.6% | -85.6% | -75.2% | -36.6% | -27.9% | +1739.6% | +299.5% | +43.7% | — | |
| Interest Coverage | -5.37 | -50.72 | 33.80 | 4.17 | -30.94 | -6.98 | -6.52 | -10.47 | -16.47 | -94.70 | — | — | -50.71 | -44.07 | -53.27 | — | -120.62 | — | -11.66 | -52.11 | -1612.09 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HCWB stock.
HCW Biologics Inc.'s current P/E is -0.0x. The average P/E over the last 1 quarters is 0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
HCW Biologics Inc.'s current operating margin is -20757.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking HCW Biologics Inc.'s business trajectory between earnings reports.